These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2368239)

  • 1. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy.
    Takashi M; Sakata T; Nagai T; Kato T; Sahashi M; Koshikawa T; Miyake K
    Urology; 1990 Jul; 36(1):96-8. PubMed ID: 2368239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.
    Miller RJ; Bahnson RR; Banner B; Ernstoff MS; O'Donnell WF
    Cancer; 1990 Jan; 65(2):207-10. PubMed ID: 2295043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.
    Scher HI; Yagoda A; Herr HW; Sternberg CN; Morse MJ; Sogani PC; Watson RC; Reuter V; Whitmore WF; Fair WR
    J Urol; 1988 Mar; 139(3):475-7. PubMed ID: 3343729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report].
    Hatano K; Kawashima A; Arai Y; Inoue H; Miyagawa Y; Takaha N; Nishimura K; Miyake O; Okuyama A
    Hinyokika Kiyo; 2006 Oct; 52(10):801-3. PubMed ID: 17131872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 8. [Primary transitional cell carcinoma of prostate: a case report].
    Uemura M; Imamura R; Inoue H; Nishimura K; Mizutani S; Miyoshi S; Mise T
    Hinyokika Kiyo; 2000 Jul; 46(7):495-8. PubMed ID: 10965459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
    Bishop JR; Moul JW; Maldonado L; McLeod DG
    Urology; 1990 Oct; 36(4):373-7. PubMed ID: 2219624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Herr H; Mazumdar M; Bacik J; Higgins G; Boyle MG; Scher HI; Bajorin DF
    J Clin Oncol; 1999 Aug; 17(8):2546-52. PubMed ID: 10561321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.
    Connor JP; Olsson CA; Benson MC; Rapoport F; Sawczuk IS
    Urology; 1989 Dec; 34(6):353-6. PubMed ID: 2595880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
    Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic changes of transitional cell carcinoma of bladder after M-VAC chemotherapy.
    Javadpour N; Daloni P
    Urology; 1989 Dec; 34(6):357-9. PubMed ID: 2595881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary carcinoma of the female urethra].
    Takahashi H; Hirano A; Nakano M; Tanaka K; Shinagawa T
    Hinyokika Kiyo; 1989 Nov; 35(11):1943-5. PubMed ID: 2618893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
    Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
    [No Abstract]   [Full Text] [Related]  

  • 19. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
    Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.